August 28, 2020
Moderna is reporting positive news from its early-stage vaccine trial. The biotech company tested out its potential vaccine in a small trial of ten adults between the ages 56 and 70 as well as 10 adults that are above the age of 70. The two doses were administered 28 days apart and proved to produce neutralizing antibodies in the patients. Researchers have continually said that antibodies are necessary to build immunity against the coronavirus. For more on the race to a vaccine, we spoke to Dr. Soren Christiansen, CEO and Chairman of Sharps Technology and former head of vaccines at Merck.